Locus Cell Co., Ltd. (TPEX:6891)

Market Cap	6.36B
Revenue (ttm)	2.36M
Net Income (ttm)	-113.02M
Shares Out	200.00M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,656
Average Volume	797,319
Open	31.60
Previous Close	31.80
Day's Range	30.65 - 32.35
52-Week Range	18.55 - 35.35
Beta	0.65
RSI	56.79
Earnings Date	Nov 13, 2025

About Locus Cell

Locus Cell Co., Ltd. focuses on contract development and manufacturing organization (CDMO) services for cell products in Taiwan and internationally. It offers tissue engineering CDMO services for adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, epithelial cells, 3D printing cell products, and other cell products; and regenerative medical product CDMO services, such as CAR-T, CAR-NK, iPSC, MSC/ADSC, and other cell types. The company is based in New Taipei City, Taiwan.

• Industry: Commercial Physical and Biological Research
• CEO: Yu-Hsiang Chang
• Employees: 53
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6891

Financial Performance

In 2024, Locus Cell's revenue was 2.36 million, an increase of 480.30% compared to the previous year's 406,000. Losses were -113.02 million, 16.6% more than in 2023.